Patents by Inventor Westin H. Morrill

Westin H. Morrill has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20200095230
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Application
    Filed: September 27, 2019
    Publication date: March 26, 2020
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • Patent number: 10442792
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Grant
    Filed: September 17, 2018
    Date of Patent: October 15, 2019
    Assignee: AbbVie Inc.
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • Publication number: 20190084966
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Application
    Filed: September 17, 2018
    Publication date: March 21, 2019
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • Patent number: 10233207
    Abstract: Provided are crystalline forms of nicotinamide riboside, including a Form I of nicotinamide riboside chloride according to formula (I). Also disclosed are pharmaceutical compositions comprising the crystalline Form I of nicotinamide riboside chloride, and methods of producing such pharmaceutical compositions. In other aspects, the present disclosure pertains to methods comprising administering to a subject the crystalline Form I of nicotinamide riboside chloride. The present disclosure also provides methods of preparing the crystalline Form I of nicotinamide riboside chloride. Also provided are a crystalline Form I of nicotinamide riboside chloride that is prepared according to any of the disclosed methods for preparing the crystalline Form I.
    Type: Grant
    Filed: October 23, 2017
    Date of Patent: March 19, 2019
    Assignee: W. R. Grace & Co.—Conn.
    Inventors: Erik C. Carlson, Michael C. Standen, Westin H. Morrill
  • Patent number: 10077256
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Grant
    Filed: November 6, 2017
    Date of Patent: September 18, 2018
    Assignee: AbbVie Inc.
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • Publication number: 20180086783
    Abstract: Provided are crystalline forms of nicotinamide riboside, including a Form I of nicotinamide riboside chloride according to formula (I). Also disclosed are pharmaceutical compositions comprising the crystalline Form I of nicotinamide riboside chloride, and methods of producing such pharmaceutical compositions. In other aspects, the present disclosure pertains to methods comprising administering to a subject the crystalline Form I of nicotinamide riboside chloride. The present disclosure also provides methods of preparing the crystalline Form I of nicotinamide riboside chloride. Also provided are a crystalline Form I of nicotinamide riboside chloride that is prepared according to any of the disclosed methods for preparing the crystalline Form I.
    Type: Application
    Filed: October 23, 2017
    Publication date: March 29, 2018
    Inventors: Erik C. Carlson, Michael C. Standen, Westin H. Morrill
  • Publication number: 20180057482
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Application
    Filed: November 6, 2017
    Publication date: March 1, 2018
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill
  • Patent number: 9809576
    Abstract: The invention provides methods of synthesizing a viral protease inhibitor in high yield, without using expensive catalysts or challenging reaction conditions.
    Type: Grant
    Filed: July 17, 2015
    Date of Patent: November 7, 2017
    Assignee: AbbVie Inc.
    Inventors: Russell D. Cink, Kirill A. Lukin, Marvin R. Leanna, Matthew J. Pelc, Timothy B. Towne, Dennie S. Welch, Kenneth M. Engstrom, Matthew M. Ravn, Richard D. Bishop, Gang Zhao, Jianzhang Mei, Jeff M. Kallemeyn, David R. Hill, Michael J. Abrahamson, Westin H. Morrill